| Name | Title | Contact Details |
|---|
Introducing QXO.
IHP offers health plan options to companies across the country, with the goal of providing affordable healthcare with a clear, and distinct, schedule of benefits. Our plans are guaranteed issue, zero deductible, and co-pay driven—well change the way you think about healthcare.
We specialize in optimizing the Human Experience by providing insights, recommendations, intelligent automation, and cognitive self-assist capabilities. Interested in how our capabilities could help your company? Please contact us at info@actiohx.com and one of our subject matter experts will be in contact with you!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.